{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T07:28:24Z","timestamp":1773386904381,"version":"3.50.1"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T00:00:00Z","timestamp":1727136000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Actelion Pharmaceuticals Ltd, a Johnson & Johnson Company"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s12325-024-02964-0","type":"journal-article","created":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T21:01:47Z","timestamp":1727211707000},"page":"4205-4227","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Macitentan and Tadalafil Combination Therapy in Incident and Prevalent Pulmonary Arterial Hypertension: Real-World Evidence from the OPUS\/OrPHeUS Studies"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1214-6723","authenticated-orcid":false,"given":"Kelly M.","family":"Chin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Channick","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick H.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gwen","family":"MacDonald","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rose","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicolas","family":"Martin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Assunta","family":"Senatore","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vallerie V.","family":"McLaughlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,9,24]]},"reference":[{"key":"2964_CR1","doi-asserted-by":"publisher","first-page":"549","DOI":"10.1183\/09031936.00057010","volume":"36","author":"M Humbert","year":"2010","unstructured":"Humbert M, Sitbon O, Ya\u00efci A, Montani D, O\u2019Callaghan DS, Jais X, et al. Survival in incident and prevalent cohorts of patients with pulmonary arterial hypertension. Eur Respir J. 2010;36:549\u201355. https:\/\/doi.org\/10.1183\/09031936.00057010.","journal-title":"Eur Respir J"},{"key":"2964_CR2","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1378\/chest.15-0300","volume":"148","author":"HW Farber","year":"2015","unstructured":"Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Muros-Le Rouzic E, et al. Five-Year outcomes of patients enrolled in the REVEAL Registry. Chest. 2015;148:1043\u201354. https:\/\/doi.org\/10.1378\/chest.15-0300.","journal-title":"Chest"},{"key":"2964_CR3","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1183\/09031936.00094112","volume":"40","author":"DP Miller","year":"2012","unstructured":"Miller DP, Gomberg-Maitland M, Humbert M. Survivor bias and risk assessment. Eur Respir J. 2012;40:530\u20132. https:\/\/doi.org\/10.1183\/09031936.00094112.","journal-title":"Eur Respir J"},{"key":"2964_CR4","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.121.024969","volume":"11","author":"KY Chang","year":"2022","unstructured":"Chang KY, Duval S, Badesch DB, Bull TM, Chakinala MM, de Marco T, et al. Mortality in pulmonary arterial hypertension in the modern era: early insights from the pulmonary hypertension association registry. J Am Heart Assoc. 2022;11: e024969. https:\/\/doi.org\/10.1161\/JAHA.121.024969.","journal-title":"J Am Heart Assoc"},{"key":"2964_CR5","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1016\/S2213-2600(16)00027-8","volume":"4","author":"AC Lajoie","year":"2016","unstructured":"Lajoie AC, Lauziere G, Lega JC, Lacasse Y, Martin S, Simard S, et al. Combination therapy versus monotherapy for pulmonary arterial hypertension: a meta-analysis. Lancet Respir Med. 2016;4:291\u2013305. https:\/\/doi.org\/10.1016\/S2213-2600(16)00027-8.","journal-title":"Lancet Respir Med"},{"key":"2964_CR6","doi-asserted-by":"publisher","first-page":"834","DOI":"10.1056\/NEJMoa1413687","volume":"373","author":"N Gali\u00e8","year":"2015","unstructured":"Gali\u00e8 N, Barber\u00e0 JA, Frost AE, Ghofrani HA, Hoeper MM, McLaughlin VV, et al. Initial use of ambrisentan plus tadalafil in pulmonary arterial hypertension. N Engl J Med. 2015;373:834\u201344. https:\/\/doi.org\/10.1056\/NEJMoa1413687.","journal-title":"N Engl J Med"},{"key":"2964_CR7","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1183\/13993003.01032-2015","volume":"46","author":"N Gali\u00e8","year":"2015","unstructured":"Gali\u00e8 N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Respir J. 2015;46:903\u201375. https:\/\/doi.org\/10.1183\/13993003.01032-2015.","journal-title":"Eur Respir J"},{"key":"2964_CR8","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","volume":"37","author":"N Gali\u00e8","year":"2016","unstructured":"Gali\u00e8 N, Humbert M, Vachi\u00e9ry JL, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J. 2016;37:67\u2013119. https:\/\/doi.org\/10.1093\/eurheartj\/ehv317.","journal-title":"Eur Heart J"},{"key":"2964_CR9","doi-asserted-by":"publisher","first-page":"3618","DOI":"10.1093\/eurheartj\/ehac237","volume":"43","author":"M Humbert","year":"2022","unstructured":"Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2022;43:3618\u2013731. https:\/\/doi.org\/10.1093\/eurheartj\/ehac237.","journal-title":"Eur Heart J"},{"key":"2964_CR10","doi-asserted-by":"publisher","first-page":"2200879","DOI":"10.1183\/13993003.00879-2022","volume":"61","author":"M Humbert","year":"2023","unstructured":"Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M, et al. 2022 ESC\/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2023;61:2200879. https:\/\/doi.org\/10.1183\/13993003.00879-2022.","journal-title":"Eur Respir J"},{"key":"2964_CR11","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12150","volume":"12","author":"VV McLaughlin","year":"2022","unstructured":"McLaughlin VV, Channick R, Kim NH, Frantz RP, McConnell J, Melendres-Groves L, et al. Safety of macitentan for the treatment of pulmonary hypertension: Real-world experience from the OPsumit\u00ae USers Registry (OPUS) and OPsumit\u00ae Historical USers cohort (OrPHeUS). Pulm Circ. 2022;12: e12150. https:\/\/doi.org\/10.1002\/pul2.12150.","journal-title":"Pulm Circ"},{"key":"2964_CR12","doi-asserted-by":"publisher","first-page":"2102024","DOI":"10.1183\/13993003.02024-2021","volume":"59","author":"MM Hoeper","year":"2022","unstructured":"Hoeper MM, Pausch C, Gr\u00fcnig E, Staehler G, Huscher D, Pittrow D, et al. Temporal trends in pulmonary arterial hypertension: results from the COMPERA registry. Eur Respir J. 2022;59:2102024. https:\/\/doi.org\/10.1183\/13993003.02024-2021.","journal-title":"Eur Respir J"},{"key":"2964_CR13","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1002\/pds.3891","volume":"17","author":"International Society for Pharmacoepidemiology","year":"2008","unstructured":"International Society for Pharmacoepidemiology. Guidelines for good pharmacoepidemiology practices (GPP). Pharmacoepidemiol Drug Saf. 2008;17:200\u20138. https:\/\/doi.org\/10.1002\/pds.3891.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2964_CR14","unstructured":"Opsumit\u00ae (macitentan). Prescribing Information. Actelion Pharmaceuticals US, Inc, a Janssen Pharmaceutical Company. March 2024."},{"key":"2964_CR15","unstructured":"Opsumit\u00ae (macitentan). Summary of Product Characteristics. Janssen Pharmaceuticals Ltd. March 2023."},{"key":"2964_CR16","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1016\/S0140-6736(02)08594-X","volume":"359","author":"SJ Pocock","year":"2002","unstructured":"Pocock SJ, Clayton TC, Altman DG. Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. Lancet. 2002;359:1686\u20139. https:\/\/doi.org\/10.1016\/S0140-6736(02)08594-X.","journal-title":"Lancet"},{"key":"2964_CR17","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1183\/13993003.00364-2015","volume":"46","author":"G Simonneau","year":"2015","unstructured":"Simonneau G, Channick RN, Delcroix M, Gali\u00e8 N, Ghofrani A, Jansa P, et al. Incident and prevalent cohorts with pulmonary arterial hypertension: insight from SERAPHIN. Eur Respir J. 2015;46:1711\u201320. https:\/\/doi.org\/10.1183\/13993003.00364-2015.","journal-title":"Eur Respir J"},{"key":"2964_CR18","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1164\/rccm.202009-3698OC","volume":"204","author":"A Boucly","year":"2021","unstructured":"Boucly A, Savale L, Ja\u00efs X, Bauer F, Bergot E, Bertoletti L, et al. Association between initial treatment strategy and long-term survival in pulmonary arterial hypertension. Am J Resp Crit Care. 2021;204:842\u201354. https:\/\/doi.org\/10.1164\/rccm.202009-3698OC.","journal-title":"Am J Resp Crit Care"},{"key":"2964_CR19","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1007\/s12325-023-02730-8","volume":"41","author":"A Muller","year":"2024","unstructured":"Muller A, Escribano-Subias P, Fernandes CC, Fontana M, Lange TJ, S\u00f6derberg S, Gaine S. Real-world management of patients with pulmonary arterial hypertension: insights from EXPOSURE. Adv Ther. 2024;41:1103\u201319. https:\/\/doi.org\/10.1007\/s12325-023-02730-8.","journal-title":"Adv Ther"},{"key":"2964_CR20","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1161\/CIRCULATIONAHA.109.911818","volume":"122","author":"M Humbert","year":"2010","unstructured":"Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Survival in patients with idiopathic, familial, and anorexigen-associated pulmonary arterial hypertension in the modern management era. Circulation. 2010;122:156\u201363. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.911818.","journal-title":"Circulation"},{"key":"2964_CR21","doi-asserted-by":"publisher","first-page":"608","DOI":"10.18553\/jmcp.2022.28.6.608","volume":"28","author":"A Ogbomo","year":"2022","unstructured":"Ogbomo A, Tsang Y, Mallampati R, Panjabi S. The direct and indirect health care costs associated with pulmonary arterial hypertension among commercially insured patients in the United States. J Manag Care Spec Pharm. 2022;28:608\u201316. https:\/\/doi.org\/10.18553\/jmcp.2022.28.6.608.","journal-title":"J Manag Care Spec Pharm"},{"key":"2964_CR22","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1161\/CIRCULATIONAHA.121.058635","volume":"146","author":"\u00c9 Tremblay","year":"2022","unstructured":"Tremblay \u00c9, Gosselin C, Mai V, Lajoie AC, Kilo R, Weatherald J, et al. Assessment of clinical worsening end points as a surrogate for mortality in pulmonary arterial hypertension: a systematic review and meta-analysis of randomized controlled trials. Circulation. 2022;146:597\u2013612. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.121.058635.","journal-title":"Circulation"},{"key":"2964_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jchf.2014.07.013","volume":"3","author":"RN Channick","year":"2015","unstructured":"Channick RN, Delcroix M, Ghofrani HA, Hunsche E, Jansa P, Le Brun FO, et al. Effect of macitentan on hospitalizations: results from the SERAPHIN trial. JACC Heart Fail. 2015;3:1\u20138. https:\/\/doi.org\/10.1016\/j.jchf.2014.07.013.","journal-title":"JACC Heart Fail"},{"key":"2964_CR24","doi-asserted-by":"publisher","first-page":"2000673","DOI":"10.1183\/13993003.00673-2020","volume":"56","author":"O Sitbon","year":"2020","unstructured":"Sitbon O, Canuet M, Picard C, Pr\u00e9vot G, Bergot E, Cottin V, et al. Initial combination therapy with macitentan and tadalafil in newly diagnosed patients with pulmonary arterial hypertension: Results from the OPTIMA trial. Eur Respir J. 2020;56:2000673. https:\/\/doi.org\/10.1183\/13993003.00673-2020.","journal-title":"Eur Respir J"},{"key":"2964_CR25","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1016\/j.jacc.2023.10.045","volume":"83","author":"E Gr\u00fcnig","year":"2024","unstructured":"Gr\u00fcnig E, Jansa P, Fan F, Hauser JA, Pannaux M, Morganti A, et al. Randomized trial of macitentan\/tadalafil single-tablet combination therapy for pulmonary arterial hypertension. J Am Coll Cardiol. 2024;83:473\u201384. https:\/\/doi.org\/10.1016\/j.jacc.2023.10.045.","journal-title":"J Am Coll Cardiol"},{"key":"2964_CR26","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1213917","volume":"369","author":"T Pulido","year":"2013","unstructured":"Pulido T, Adzerikho I, Channick R, Delcroix M, Gali\u00e8 N, Ghofrani A, et al. Macitentan and morbidity and mortality in pulmonary arterial hypertension. N Engl J Med. 2013;369:809\u201318. https:\/\/doi.org\/10.1056\/NEJMoa1213917.","journal-title":"N Engl J Med"},{"key":"2964_CR27","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.116.003896","author":"A Wei","year":"2016","unstructured":"Wei A, Gu Z, Li J, Liu X, Han Y, Pu J. Clinical adverse effects of endothelin receptor antagonists: insights from the meta-analysis of 4894 patients from 24 randomized double-blind placebo-controlled clinical trials. J Am Heart Assoc. 2016. https:\/\/doi.org\/10.1161\/JAHA.116.003896.","journal-title":"J Am Heart Assoc"},{"key":"2964_CR28","doi-asserted-by":"publisher","first-page":"253","DOI":"10.2147\/VHRM.S133921","volume":"14","author":"M Correale","year":"2018","unstructured":"Correale M, Ferraretti A, Monaco I, Grazioli D, Di Biase M, Brunetti ND. Endothelin-receptor antagonists in the management of pulmonary arterial hypertension: where do we stand? Vasc Health Risk Manag. 2018;14:253\u201364. https:\/\/doi.org\/10.2147\/VHRM.S133921.","journal-title":"Vasc Health Risk Manag"},{"key":"2964_CR29","doi-asserted-by":"publisher","first-page":"2102311","DOI":"10.1183\/13993003.02311-2021","volume":"60","author":"MM Hoeper","year":"2022","unstructured":"Hoeper MM, Pausch C, Olsson KM. COMPERA 2.0: a refined four-stratum risk assessment model for pulmonary arterial hypertension. Eur Respir J. 2022;60:2102311. https:\/\/doi.org\/10.1183\/13993003.02311-2021.","journal-title":"Eur Respir J"},{"key":"2964_CR30","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1161\/CIRCULATIONAHA.109.898122","volume":"122","author":"RL Benza","year":"2010","unstructured":"Benza RL, Miller DP, Gomberg-Maitland M, Frantz RP, Foreman AJ, Coffey CS, et al. Predicting survival in pulmonary arterial hypertension: insights from the Registry to Evaluate Early and Long-Term Pulmonary Arterial Hypertension Disease Management (REVEAL). Circulation. 2010;122:164\u201372. https:\/\/doi.org\/10.1161\/CIRCULATIONAHA.109.898122.","journal-title":"Circulation"},{"key":"2964_CR31","doi-asserted-by":"publisher","first-page":"4175","DOI":"10.1093\/eurheartj\/ehx257","volume":"39","author":"D Kylhammar","year":"2017","unstructured":"Kylhammar D, Kjellstrom B, Hjalmarsson C, Jansson K, Nisell M, Soderberg S, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2017;39:4175\u201381. https:\/\/doi.org\/10.1093\/eurheartj\/ehx257.","journal-title":"Eur Heart J"},{"key":"2964_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/pul2.12258","volume":"13","author":"HW Farber","year":"2023","unstructured":"Farber HW, Chakinala MM, Cho M, Frantz RP, Frick A, Lancaster L, et al. Characteristics of patients with pulmonary arterial hypertension from an innovative, comprehensive real-world patient data repository. Pulm Circ. 2023;13: e12258. https:\/\/doi.org\/10.1002\/pul2.12258.","journal-title":"Pulm Circ"},{"key":"2964_CR33","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1086\/678514","volume":"4","author":"ME Pugh","year":"2014","unstructured":"Pugh ME, Hemnes AR, Trammell A, Newman JH, Robbins IM. Variability in hemodynamic evaluation of pulmonary hypertension at large referral centers. Pulm Circ. 2014;4:679\u201384. https:\/\/doi.org\/10.1086\/678514.","journal-title":"Pulm Circ"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02964-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-024-02964-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-024-02964-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,15]],"date-time":"2024-10-15T18:11:35Z","timestamp":1729015895000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-024-02964-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9,24]]},"references-count":33,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["2964"],"URL":"https:\/\/doi.org\/10.1007\/s12325-024-02964-0","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,9,24]]},"assertion":[{"value":"23 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 August 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 September 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Kelly M Chin has served as a Scientific Committee member for Johnson & Johnson; has received research grants \/ support from Johnson & Johnson, Altavant, Acceleron, United Therapeutics, Pfizer, Merck, Gossamer Bio; has received support for travel to meetings from Johnson & Johnson; and has received consultancy fees from Johnson & Johnson, Altavant, Acceleron, United Therapeutics, Gossamer Bio and Merck. Richard Channick served as a Scientific Committee member for Johnson & Johnson; served on an advisory board for Johnson & Johnson and Bayer; received research grants \/ support from Johnson & Johnson and United therapeutics; received speaker fees from Johnson & Johnson, and Bayer; received consultancy fees from Johnson & Johnson, Bayer and Third pole. Nick H Kim has served a Scientific Committee member for Johnson & Johnson; has received research grants \/ support from Enzyvant and Lung Biotechnology; has received consultant fees from Johnson & Johnson, Bayer, Merck, United Therapeutics, Gossamer Bio, Pulnovo, and Polarean; and received speaker fees from Johnson & Johnson, Bayer and Merck. Rose Ong is an employee of Actelion Pharmaceuticals Ltd, a Johnson & Johnson Company, holds stock\/stock options in Johnson & Johnson and spouse is an employee of Roche. Gwen MacDonald and Nicolas Martin are employees of Actelion Pharmaceuticals Ltd, a Johnson & Johnson Company and hold stock\/stock options in Johnson & Johnson. Assunta Senatore is an employee of Actelion Pharmaceuticals Ltd, a Johnson & Johnson Company. Vallerie V McLaughlin served as a Scientific Committee member for Johnson & Johnson; received research grants from Aerovate, Altavant, Gossamer Bio, Johnson & Johnson, Merck, and SoniVie; and received consultant fees from Aerami, Aerovate, Altavant, Bayer, Caremark, Corvista, Gossamer Bio, Johnson & Johnson, L.L.C, Merck and United Therapeutics.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The OPUS and OrPHeUS studies were conducted according toGood Pharmacoepidemiology Practices and the 2008 Declaration of Helsinki ethical principles. Ethical approval was received from independent ethics committees\/institutional review boards (IRB) of participating centers (Supplementary Appendix I). The protocols were reviewed by the US FDA with written informed consent obtained from all patients in OPUS, including for publication of anonymized patient data (informed consent was not required in OrPHeUS as an IRB waiver was obtained). The Informed Consent Form in OPUS included a confidentiality clause that all records and documents pertaining to the participation of patients in the OPUS registry would be held strictly confidential and their names would not be reported in any publications resulting from the OPUS registry. IRB approvals were provided by WIRB and Quorum (now Advarra) (OPUS registry; WIRB approval number 2014\u20100816, Quorum Review File number 29120\/Advarra Pro00035124) and WCG\u2010IRB (OrPHeUS study; IRB numbers 2017\u20108051 and 2017\u20102348).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}